Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTLP Injection to Accelerate Immune Reconstitution After UCB Transplantation in Hematologic Malignancies
NCT04707300Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2022
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of human T lymphoid progenitor in hematologic malignancy, sponsored by Assistance publique - Hôpitaux de Paris. Started Feb 2022; status: recruiting.
02
Drugs
human T lymphoid progenitor
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT04707300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04707300.